Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
| العنوان: | Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. |
|---|---|
| المؤلفون: | Jerkeman, Mats, Aman, P, Cavallin-Ståhl, Eva, Torlakovic, E, Åkerman, Måns, Mitelman, Felix, Fioretos, Thoas |
| المصدر: | International Journal of Oncology. 20(1):161-165 |
| مصطلحات موضوعية: | Gene Rearrangement B-Lymphocyte : genetics, Human, Immunophenotyping, Lymphoma B-Cell : drug therapy : genetics, Leucovorin : therapeutic use, Lactate Dehydrogenase : metabolism, Lymphoma Large-Cell Diffuse : drug therapy : genetics, Male, Methotrexate : therapeutic use, Middle Age, Neoplasm Staging, Prednisone : therapeutic use, Prognosis, Proto-Oncogene Proteins : genetics, Support Non-U.S. Gov't, Vincristine : therapeutic use, Transcription Factors : genetics, Doxorubicin : therapeutic use, DNA-Binding Proteins : genetics, DNA Neoplasm : analysis : metabolism, Cyclophosphamide : therapeutic use, Blotting Southern, Bleomycin : therapeutic use, Antineoplastic Combined Chemotherapy Protocols : therapeutic use, Aged, Adolescence, Adult, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology |
| الوصف: | The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables. |
| الوصول الحر: | https://lup.lub.lu.se/record/107004Test http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11743658Test http://147.52.72.117/IJO/2002/volume20/number1/161-165.pdfTest |
| قاعدة البيانات: | SwePub |
| تدمد: | 10196439 |
|---|